Losing 19.7% weight in 24 weeks! Federal Pharmaceutical X Novo Nordisk GLP-1/GIP/GCG triple target agonist weight loss phase 1 study successful
On February 24, 2026, FedEx International Holdings Limited (FedEx) and Novo NordiskAS jointly released the main results of the Phase 11 clinical trial of GLP-1/GIP/GCG triple target receptor agonist JBT251 in China.
Semaglutide Powder CAS 910463-68-2
1.We supply
(1)Tablet
(2)Gummies
(3)Capsule
(4)Spray
(5)API(Pure powder)
(6)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-4-008
Semaglutide CAS 910463-68-2
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide Semaglutide Powder, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html
UBT251 is jointly developed by Federal Biotech (Zhuhai Hengqin) Co., Ltd. (Federal Biotech), a wholly-owned subsidiary of Federal Pharmaceuticals, and Novo Nordisk under a licensing agreement signed in March 2025. Federal Biotech is responsible for development in mainland China (Mainland China), Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan, while Novo Nordisk is responsible for global development in addition to the aforementioned.
This clinical study was conducted by Federal Biotech to investigate the safety and efficacy of weekly injections of 2mg, 4mg, and 6mg doses of UBT251 in overweight or obese patients in China compared to placebo controls. The baseline average weight of the patient was 92.2kg. After 24 weeks of treatment, the UBT251 treatment group showed the highest average weight loss of 19.7% (-17.5kg), while the placebo group only had a decrease of 2.0% (-1.6kg).
In addition, compared with the placebo group, all dose groups of UBT251 showed statistically significant improvements in key secondary endpoints, including waist circumference, blood glucose, blood pressure, and blood lipids.
In this study, UBT251 showed good safety and tolerability. The most common adverse event is gastrointestinal reactions, the vast majority of which are mild to moderate and gradually alleviate over time, consistent with therapy based on enteropancreatin.
2.1 billion US dollars! Novo Nordisk is betting on the next generation of oral weight loss drugs
On February 25, 2026, Novo Nordisk and Vivtex announced the establishment of a cooperative relationship to jointly develop the next generation of oral biological agents for the treatment of obesity, diabetes and related complications. According to the terms of the agreement, Vivex will license some oral drug delivery technologies to Novo Nordisk, and is eligible for up to $2.1 billion in upfront payments, milestone payments for research funding, and graded royalties for future product sales.
Specifically, this collaboration aims to achieve oral administration of biopharmaceutical candidate drugs, which are typically only administered by injection due to poor absorption in the gastrointestinal tract. This collaboration combines Novo Nordisk's profound expertise in peptide and protein drugs with Vvtex's proprietary gastrointestinal screening and formulation platform to develop the next generation of oral drugs. Based on the cooperation agreement between both parties, Novo Nordisk will be responsible for the global development, regulatory affairs, production, and commercialization of related products.
GSK hepatitis B AS0 Therapy Bepirovirsen declared for listing in Japan
On February 26, 2026, GlaxoSmithKline (GSK) announced that Beplovirsen, a new drug for steamed hepatitis B, had submitted an application for listing in Japan. GSK believes that Beplovirsen is expected to become the first drug to achieve functional cure of chronic hepatitis B.
Bepirovesen is an antisense oligonucleotide (ASO) therapy introduced by GSK from Ionis, aimed at inhibiting the replication of hepatitis B virus DNA, thereby suppressing the level of hepatitis B surface antigen (HBsAg) in the blood and stimulating the immune system to produce a persistent response. This drug is the first small nucleic acid drug in the field of chronic hepatitis B that has completed the Sichuan phase research. This listing application is based on positive data from two Phase I studies (B-Wel1 and B-Well2).
The study evaluated the functional curative effect, safety, pharmacokinetics and efficacy persistence of Bepirovirsen compared with placebo in chronic hepatitis B patients treated with nucleoside analogues and with baseline HBSAg ≤ 3000IU/ml. The primary endpoint is the functional cure rate of patients with baseline HBsAg ≤ 3000IU/ml, and the key secondary endpoint is the functional cure rate of patients with baseline HBsAg ≤ 1000IU/ml.
Eli Lilly Orforglipron defeated oral semaglutide head to head, achieving dual advantages in reducing blood sugar and weight
On February 26, 2026, Lilly announced the detailed results of the ACHIEVE-3 study. ACHIEVE-3 is the first head to head controlled study in this research series, which aims to evaluate the safety and effectiveness of orforglipron and oral smeglutide in type 2 diabetes adults with poor blood glucose control treated with two muscles.
Orforglipron is a small molecule oral GLP-1 receptor agonist that is taken without dietary or water restrictions. The study lasted for 52 weeks and included 1698 participants, divided into four active treatment groups: orforglipron 12mg and 36mg, as well as oral semaglutide 7mg and 14mg. In the ACHIEVE-3 study, orforglipron outperformed oral semaglutide in the primary endpoint and all key secondary endpoints, achieving significant improvements in reducing A1C and weight improvement.
The ACHIEVE-3 study showed that the overall safety and tolerability of orforglipron are consistent with previous studies. The most common adverse reactions of orforglipron and oral semaglutide are nausea, diarrhea, vomiting, indigestion, and decreased appetite. Among them, the discontinuation rates of 0rforglipron due to adverse events were 8.7% in the 12mg group and 9.7% in the 36mg group, respectively; The discontinuation rate of oral semaglutide was 4.5% in the 7mg group and 4.9% in the 14mg group.
Orforglipron is a small molecule (non peptide) glucagon like peptide-1 receptor agonist (GLP-1 RA) that is currently under development and administered orally once daily. This medication can be taken at any time of the day without restrictions on diet and water intake. This drug was discovered by ChugaiI Pharmaceutical Co., Ltd and authorized to be developed by Eli Lilly in 2018. Zhongwai Pharmaceutical and Eli Lilly jointly published preclinical pharmacological data for this molecule.